Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial.
7081 Background: PON is a potent, oral, pan-BCR-ABL inhibitor with activity against native and mutant forms of BCR-ABL, including the resistant T315I mutant. The efficacy and safety of PON (45 mg QD) were evaluated in the phase 2 PACE trial. Methods: 449 pts resistant or intolerant (R/I) to dasatinib or nilotinib or with the T315I mutation were enrolled. Data are as of 3 Sept 2013; median follow-up 24 (0.1-35) mo. NCT01207440. Results: Pts were heavily pretreated: 58% received ≥3 TKIs. 42% remained on study (55% CP-CML). The most common reasons for discontinuation: PD (21%) and AEs (14%, most common was thrombocytopenia, 4%). Table shows response rates at any time. In CP-CML, 89% pts maintained MCyR for at least 2 yr; progression-free survival (PFS) and overall survival (OS) at 2 yr were 67% and 86%. For AP-CML, BP-CML, and Ph+ ALL, OS at 2 yr was 72%, 18%, and 21%, respectively. Most common treatment-emergent AEs (≥30%) were thrombocytopenia (43%), rash (40%), abdominal pain (40%), headache (36%), consti...